Summary Drug resistance is a major obstacle to successful chemotherapy of primary liver cancer, which is associated with high expression of the multidrug resistance (MDR) gene product P-glycoprotein (Pgp), a multidrug efflux transporter. The most effective single agents in treatment of primary liver carcinoma belong to the anthracycline family, yet several anthracyclines are known to be substrates for Pgp. In the present study, we compared four anthracycines with respect to cell growth inhibition, intracellular accumulation and cellular efflux using the HB8065/R human hepatoma cell line which is rich in Pgp, and the Pgp-poor parental line HB8065/S. The anthracyclines were also administered in conjunction with the Pgp-modifying agents verapamil and SDZ PSC 833 to assess modulation of resistance. The HB8065/R cells were sensitive to aclarubicin (ACL) and highly resistant to epirubicin (EPI), doxorubicin (DOX) and daunorubicin (DNR). SDZ PSC 833 enhanced accumulation, decreased efflux and increased cytotoxicity of EPI, DOX and DNR in the HB8065/R cells, but none of these effects was seen with ACL. In conclusion, ACL is apparently not transported by Pgp and retains its activity in a multidrug-resistant human hepatoma cell line; such properties can be exploited for clinical purposes.
Cancer chemotherapy has major limitations because multidrug resistance (MDR) frequently prevents successful treatment outcome in various human cancers. One important mechanism of MDR is expulsion of certain anti-cancer drugs (MDR drugs) from the interior of the malignant cells by means of the multidrug efflux transporter P-glycoprotein (Pgp), which enables the malignant cells to maintain tolerable intracellular levels of these drugs (Juliano and Ling, 1976; Endicott and Ling, 1989) . Pgp expression has been shown to correlate negatively with chemosensitivity and survival in leukaemias (Campos et al., 1992; Marie et al., 1991) , lymphomas (Yuen and Sikic, 1994) , childhood sarcomas (Chan et al., 1990) , neuroblastomas (Chan et al., 1991) and ovarian carcinomas (Baekelandt et al., 1994) .
Primary liver cancer is one of the most frequently fatal human malignancies, and the response rate to chemotherapy is less than 20% for a series of drug regimens (Falkson et al., 1984) . Overexpression of Pgp has been reported in 33-75% of patients at diagnosis (Teeter et al., 1993; Itsubo et al., 1994) . Therefore, circumvention of Pgp-mediated MDR might improve the prognosis of unresectable hepatocellular carcinoma. Unfortunately, most of the clinically important anthracyclines appear to be substrates for Pgp (reviewed by Scambia et al., 1994) . Among these are the type I anthracyclines epirubicin (EPI), doxorubicin (DOX) and daunorubicin (DNR), which preferentially inhibit the synthesis of DNA. The type II anthracycline aclarubicin (ACL), which consists of a 9-alkyl-aglycone (aklavinone) and a trisaccharide (rhodosamine, 2-deoxyfucose and L-cinerulose A), differs from EPI, DOX and DNR with respect to mechanism of action, as ACL preferentially inhibits RNA synthesis (Muggia and Green, 1991) . The 9-alkyl substitution of the anthracene A ring and certain sugar modifications have also been associated with reduced affinity for Pgp and retention of cytotoxic activity in certain MDR tumour cell lines (Coley et al., 1990) . Thus, ACL has some structural characteristics in favour of MDR circumvention as opposed to EPI, DOX and DNR (Figure 1 ).
ACL has a wide range of activity in tumours and human xenografts (Hori et al., 1977; Oki et al., 1981) , and shares the toxic effects of the other anthracyclines, although it appears to be less cardiotoxic (Dantchev et al., 1979; Mortensen, 1987) . The cytotoxic activity of ACL is reported to be retained in MDR variants of a mouse mammary tumour line and a human small-cell lung cancer line (Coley et al., 1989 (Coley et al., , 1993 . In clinical trials, several cases of complete remissions have been reported with ACL in DNR-resistant acute myeloid leukaemia (Machover et al., 1984; PedersenBjergaard et al., 1984) . In unresectable hepatocellular carcinoma, tumour-targeting chemotherapy with ACL has been reported as highly effective, and patients with unknown Pgp status have achieved response rates of 43-50% (Beppu et al., 1991; Ichikara et al., 1989) . The possible relationship between a favourable response to ACL and circumvention of Pgp-mediated MDR warrants study, which could be done in vitro using a hepatoma cell line expressing high levels of Pgp.
In our laboratory, resistance to the second-generation anthracycline epirubicin has been developed in a human hepatoma cell line (HB8065) that has retained differentiated liver cell functions (Knowles et al., 1980; Hall et al., 1991) . This resistant subline expresses high levels of Pgp compared with the parental line (Lehne et al., 1994) . In the present study, the cytotoxicity and the cellular pharmacokinetics of ACL, EPI, DOX and DNR were compared in the absence or presence of the calcium channel blocker verapamil and the novel cyclosporin D analogue SDZ PSC 833. Apparently, certain calcium channel blockers and cyclosporins bind to Pgp and counteract the active outward transport of MDR drugs (Cornwell et al., 1987; Foxwell et al., 1989; Boesch et al., 1991; Friche et al., 1992) . The objective of the present study was to investigate the selectivity of Pgp-mediated resistance to different anthracyclines in human hepatoma cells by assessments of cell growth inhibition, intracellular drug accumulation, cellular drug efflux and response to resistance modifiers.
Materials and methods

Chemicals
The cells were propagated in Eagle's modified minimum essential medium (EMEM; Bio Whittaker, Walkersville, MA, USA), supplemented with 10% fetal calf serum, L-glutamine (0.05 m mmol ml-1), streptomycin (100 ug ml-'), penicillin (100 u ml -'), and nystatin (40 u ml'-). Cell growth inhibition The HB8065/S and HB8065/R cell lines also differed with respect to susceptibility to anthracyclines, using growth inhibition as a measure of cytotoxicity. After continuous treatment of HB8065/R cells with EPI, DOX, DNR and ACL for 3 days, the G150 values were 2118 ng ml-', 1784 ng ml-', 362 ng ml-' and 38 ng ml-' respectively. The corresponding G150 values for HB8065/S cells were 46 ng ml-', 39 ng ml-', 40 ng ml-' and 29 ng ml-', which resulted in RF values of 46, 46, 9 and 1 respectively ( Figure  3) . Hence, the HB8065/R cells were sensitive to ACL but resistant to EPI, DOX and DNR.
To test if the variation in anthracycline resistance was correlated with Pgp activity, growth inhibition studies were carried out in the presence of SDZ PSC 833, which is a potent modifier of Pgp-mediated MDR (Boesch et al., 1991) . After treatment with SDZ PSC 833, the GIs of HB8065/R increased by a factor of 46 (modifying factor, MF) for EPI (G1_0 untreated, 1878 ng ml-'; G150 treated, 41 ng ml-'), 45 for DOX (Glso untreated, 1967 ng ml-'; GIso treated, 44 ng ml-') and 11 for DNR (GI50 untreated, 375 ng ml-'; GI50 treated, 34 ng ml-') (Figure 4a-c) . There was practically no change in G150 for ACL (GI,0 untreated, 43 ng ml-', G150 treated, 36 ng ml-') ( Figure 4d) . Thus, the resistance to EPI, DOX and DNR was eliminated by SDZ PSC 833, while there was no change in the cytotoxicity of ACL. Even when the treatment duration was reduced from 3 days to 3 h, the sensitivity of HB8065/R cells to ACL persisted, the RF values being 1 for ACL (GI50 HB8065/S, 356 ng ml-'; G150 HB8065/R, 467 ng ml-'), 20 for EPI (GI50 HB8065/S, 250 ng ml-'; G150 HB8065/R, 5000 ng ml-1), 17 for DOX (GI50 HB8065/S, 286 ng ml-'; G150 HB8065/R, 4900 ng ml-') and 23 for DNR (Gl50 HB8065/S, 184 ng ml-', G150 HB8065/R, 4295 ng ml-'). SDZ PSC had absolutely no effect on the cytotoxicity of EPI or ACL in the sensitive HB8065/S cells and the growth curves of modified and non-modified cells were practically identical (data not shown). (Figure 6a-d) . Assuming that the slope of the regression line represents a measure of intracellular drug retention, the HB8065/S cells accumulate 2.6 times more EPI, 2.3 times more DNR and 1.6 times more DOX than HB8065/R cells. In contrast, incubation with ACL for 1 h led to 1.7 times higher intracellular levels in the HB8065/R cells, despite the relatively high expression of Pgp in these cells compared with the parental HB8065/S cells. The total fluorescence from each anthracycline differed in intensity, and at a drug concentration of 5 ,ug ml-' the fluorescence intensity of DNR was 4.3-fold that of ACL, 3.6-fold that of DOX and 3.5-fold that of EPI in HB8065/R cells. Individual profiles of drug fluorescence in resistant (R) and sensitive (S) hepatoma cells during 3 h incubation with each anthracycline are presented in Figure 7 . Flow cytometric measurements revealed a rapid influx of all four anthracyclines in both HB8065/R and HB8065/S cells. The rate of anthracycline accumulation appeared to be similar for the two cell types in the first few minutes of incubation. DOX and DNR at intracellular levels of 1.9, 1.7 and 2.1 times those in the resistant cells. On the other hand, the resistant cells accumulated 1.4 times more ACL than the sensitive cells.
Modification of membrane transport
The resistant HB8065/R cells were incubated for 90 min with 5 Mg ml-' of each anthracycline alone or in combination with verapamil (5 ,ug ml-') or SDZ PSC 833 (1.5 jg ml-). The two modifying agents were added to the cells after 30 min and pronounced changes in drug fluorescence appeared immediately (Figure 8 ). The addition of VPL and SDZ PSC 833 resulted in 2-to 3-fold enhancement of the cellular fluorescence of DNR, DOX and EPI. In contrast, essentially no change was seen in the fluorescence of ACL after treatment with either VPL or SDZ PSC 833. If the changes in intracellular drug fluorescence were induced by interaction between the modifying agent and Pgp, a corresponding change in drug efflux should occur as well. The results of the drug efflux studies are summarised in Table I . We measured significant reductions of effluxed EPI, DOX and DNR from HB8065/R cells after treatment with SDZ PSC 833 (1.5 Mg ml-'), but no change was seen in the efflux of ACL. On the other hand, identical treatment of the sensitive HB8065/S cells was not accompanied by significant changes in the efflux of any of the anthracyclines.
Discussion
Several mechanisms of MDR have been described in murine and human cancer cell lines. Apparently, the most common form of MDR is Pgp-mediated increased drug efflux resulting in decreased intracellular drug concentrations. Pgp has a broad specificity to multiple hydrophobic xenobiotics (reviewed by Licht et al., 1994) , and many anthracyclines have been shown to be substrates of Pgp (Mulder et al., 1995) . In tumour cell lines, non-Pgp-mediated resistance to anthracyclines has been linked to reduced activity of topoisomerase II (Cole et al., 1991; Eijdems et al., 1995) , increased activity of glutathione S-transferase (Batist et al., 1986) and reduced activity of cytochrome P450 reductase (Mimnaugh et al., 1989) . Recently, a new multidrug efflux transporter, multidrug resistance protein (MRP), has been identified (Cole et al., 1992) , and overexpression of Pgp and MRP may coexist (Brock et al., 1995) .
Our results show that the HB8065/R cells remain sensitive to ACL despite a pronounced overexpression of Pgp, and that ACL accumulates unabated in these cells. The Pgpmodifying agents used in this study did not influence the cytotoxicity, accumulation or efflux of ACL. On the other hand, treatment of HB8065/R cells with SDZ PSC 833 increased the accumulation and decreased the efflux of EPI, DOX and DNR, resulting in multiplied sensitivity, which became equal to that of the parental HB8065/S cells. Thus, Pgp seemed to be the key determinant to explain the difference in cytotoxicity and cellular pharmacokinetics seen in the four anthracyclines. Our findings strongly indicate that ACL is a poor substrate for active outward transport by Pgp, which is in agreement with previous reports of MDR circumvention with 9-alkyl or morpholinyl substituted anthracyclines in cell lines (Scott et al., 1986; Streeter et al., 1986; Coley et al., 1990) . Two recent reports suggest that ACL may also circumvent drug resistance due to altered expression of topoisomerase II and glutathione S-transferase (Jensen et al., 1993; Okuyama et al., 1994) . The assessment of cytotoxicity was performed using growth inhibition assays that measure cell growth by electronic cell counting. Previous attempts to perform colony-forming assays in HB8065/R and HB8065/S cells have been unsuccessful because both lines failed to clone reproducibly on soft agar (Hall et al., 1991) . Although electronic assessment of growth inhibition does not discriminate between cells of poor or of good proliferating capacity, the results from growth inhibition assays of anthracycline toxicity have been shown to correlate with those of clonogenic assays in certain pairs of parental and MDR cell lines (Bhalla et al., 1985; Hall et al., 1991) . Following a 3 h treatment course the growth inhibition assay revealed a 20-fold resistance to EPI, DOX and DNR in the resistant human hepatoma cell line relative to the parental line, which corresponded with approximately 2-fold lower intracellular drug accumulation in the resistant cells than in the parental cells. By extending the treatment duration to 3 days, the resistance to EPI and DOX was doubled and the resistance to DNR was halved. Thus, the dose -response relationship was schedule dependent. Correspondingly, it has previously been demonstrated that cell killing by doxorubicin is an exponential function of drug exposure time in Chinese hamster ovary cells (Bates et al., 1985) , and that lengthening the drug exposure time reduces the relative resistance to vincristine in two human colon carcinoma cell lines .
Using flow cytometry, we demonstrated rapid accumulation of all the anthracyclines in both cell types within minutes of incubation, which is in agreement with previous in vitro and in vivo findings of rapid influxes of anthracyclines across cellular membranes (Meriwether & Bachur, 1972; Egorin et al., 1974; Bachur, 1976) . In both hepatoma cell lines, the fluorescence of DNR and ACL reached a plateau within 15 min. It was previously shown that ACL accumulates more rapidly than DNR or DOX in L1210 ascitic cells (Zenebergh et al., 1982) , and that the rate of cellular uptake increases by increasing lipophilicity of the anthracyclines (Skovsgaard, 1987; Wheeler and Kessel, 1980) . EPI and DOX reached a plateau within 15 min in the resistant cells but continued to accumulate for 45-150 min in the parental cells. Thus, the drug accumulation was not only governed by physicochemical characteristics of the drugs, but also by cellular characteristics.
The confocal laser microscopic images confirmed the flow cytometric findings by showing less fluorescent brightness of EPI, DOX and DNR in the resistant cells than in the sensitive ones, and by showing no difference in fluorescent brightness of ACL in the two cell types. It has been demonstrated by others that the fluorescence intensity of intracellular DNR parallels measurements of uptake of the corresponding radioactive drug (Bhalla et al., 1985) . However, the intracellular anthracycline fluorescence does not accurately reflect the drug content because binding to DNA may cause quenching of the fluorescence, which is particularly pronounced for ACL (Skovsgaard, 1987;  al., 1989) . The fluorescence intensity of free ACL has been measured to be 200 times that of nucleus-bound drug (Millot et al., 1989) . In the cytoplasm of the HB8065/S cells, and to a much lesser extent in the resistant HB8065/R cells, the anthracycline fluorescence appeared in numerous cytoplasmic vesicles. Similar vesicles have been demonstrated in both MDR cell lines and corresponding parental lines (Weaver et al., 1991) , and may represent drug accumulation in lysosomes. It is possible that higher drug concentrations may activate non-specific adsorptive endocytosis, which has been demonstrated in anthracycline-resistant Ehrlich ascites tumour cell lines (Sehested et al., 1987) .
Our results showed that low accumulation of EPI and DOX paralleled high efflux of these cytotoxics in the pair of cell lines studied. Because SDZ PSC 833 significantly reduced the efflux of EPI, DOX and DNR from the resistant human hepatoma cells but not from the sensitive ones, it is likely that Pgp was mainly responsible for the variations in the efflux of these anthracyclines. The efflux of ACL was not altered by SDZ PSC 833 in any of the cell types, and the greater efflux of ACL from the resistant human hepatoma cells was obviously unrelated to Pgp, but correlated with an increased accumulation of ACL in the resistant cells. Interestingly, it has been reported that there is no difference in the efflux of ACL between parental and resistant lines of human small-cell lung cancer and mouse mammary tumour (Coley et al., 1993) . Thus, there may exist alternative transport mechanisms for ACL in certain cell types that may also express high levels of Pgp.
The applied anthracycline doses in this study were in the upper range or slightly above achievable plasma concentrations in patients after standard bolus i.v. injections (Martini et al., Paul et al., 1989 ). An-i.v. bolus injection of 60-120 mg m-2 ACL yields initially 2-3 nmol 1' (Egorin et al., , which is approximately half of the highest applied dose of ACL in this study. The verapamil dose that restored the net drug accumulation in HB8065/R cells to the level of HB8065/S cells or above was approximately 10 times a clinically relevant plasma concentration in cardiac patients (Frishman et al., 1982) . On the other hand, it has been shown in rats that verapamil concentrates 40-fold in liver tissue compared with plasma (Hamann et al., 1983) . The SDZ PSC 833 dose that we applied in the culture media was similar to tolerable plasma concentrations obtained with the drug in clinical trials (Sonneveld et al., 1994) and thus this drug seems more clinically promising. In the present study, a comparison of four different anthracyclines with respect to cytotoxicity, intracellular accumulation, cellular efflux and response to Pgp-modifying agents strongly indicates Pgp as the major resistance mechanism responsible for the difference that has been demonstrated between ACL and the type I anthracyclines EPI, DOX and DNR. Therefore, we may conclude that the 9-alkyl trisaccharide ACL appears to be a poor substrate of Pgp in cultured human hepatoma cells. Translation of this unique feature of ACL into clinical practice would mean that treatment of unresectable hepatocellular carcinoma may benefit from tailoring the chemotherapeutic regimens according to the Pgp status of the tumour.
